Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2254126 | 0.94 | CYP2A6 (0.50) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL2252619 | 0.94 | CYP2A6 (0.50) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL314646 | 0.94 | CYP2A6 (0.54) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL7193058 | 0.79 | CYP1A2 (0.34) | CYP2A6CYP1A2RAB9ANQO1CA12 | |
| SCHEMBL578349 | 0.79 | NQO1 (0.45) | CYP1A2NQO1KDM4EMEN1POLB | |
| SCHEMBL4588144 | 0.79 | ALDH1A1 (0.41) | CYP1A2RAB9ANQO1KDM4EMEN1 | |
| SCHEMBL443528 | 0.78 | CYP2A6 (0.80) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL29367032 | 0.78 | CYP2A6 (0.80) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL443070 | 0.78 | CYP1A2 (0.79) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A | |
| SCHEMBL29447161 | 0.78 | CYP1A2 (0.79) | CYP2A6CYP1A2HSD17B1HSD17B2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028585-B | Arylalkylazole derivative and application thereof | 聊城大学 | 2023-08-18 | — | — | CN | claimed |
| CN-115028585-A | Arylalkanazole derivatives and use thereof | 聊城大学 | 2022-09-09 | — | — | CN | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| EP-2892892-B1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-31 | — | — | EP | claimed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | claimed |
| EP-1778639-B1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RES INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-9085531-B2 | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-21 | — | — | US | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-4071621-A | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-31 | — | — | US | claimed |
| US-4069318-A | INHIBITION AND SUPPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-17 | — | — | US | claimed |
| US-4066758-A | ANTITHROMBOTIC | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-01-03 | — | — | US | claimed |
| US-4055651-A | THROMBOSIS INHIBITORS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-10-25 | — | — | US | claimed |
| US-4055636-A | THROMBOSIS INHIBITORS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-10-25 | — | — | US | claimed |
| US-4046876-A | THROMBIN INHIBITORS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-09-06 | — | — | US | claimed |
| US-4041156-A | ANTITHROMBOGENIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1977-08-09 | — | — | US | claimed |
| US-4036955-A | TREATMENT OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-07-19 | — | — | US | claimed |
| US-4018913-A | N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-04-19 | — | — | US | claimed |
| US-4018915-A | ANTITHROMBOTIC | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1977-04-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP2A6 1519/4885CYP1A2 439/4885HSD17B1 353/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CYP2A6 1519/4885CYP1A2 439/4885HSD17B1 353/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP2A6 1519/4885CYP1A2 439/4885HSD17B1 353/4885 |
| US-20140243524-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | DRD4, SLC6A4, HTR4 | CYP2A6 742/4885CYP1A2 146/4885HSD17B1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.